CANTARGIA AB has a total of 55 patent applications. It increased the IP activity by 0.0%. Its first patent ever was published in 2009. It filed its patents most often in United States, EPO (European Patent Office) and China. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are INTREAT PTY LTD, NOVELMED THERAPEUTICS INC and TOLERRX INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 10 | |
#2 | EPO (European Patent Office) | 9 | |
#3 | China | 6 | |
#4 | Australia | 5 | |
#5 | WIPO (World Intellectual Property Organization) | 5 | |
#6 | Canada | 4 | |
#7 | Mexico | 4 | |
#8 | Brazil | 3 | |
#9 | United Kingdom | 3 | |
#10 | Republic of Korea | 3 | |
#11 | Israel | 2 | |
#12 | Singapore | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement | |
#4 | Telecommunications | |
#5 | Control |
# | Name | Total Patents |
---|---|---|
#1 | Fioretos Thoas | 44 |
#2 | Järås Marcus | 25 |
#3 | Von Wachenfeldt Karin | 21 |
#4 | Svedberg Agneta | 20 |
#5 | Malmborg Hager Cecilia Ann-Christin | 17 |
#6 | Jaras Marcus | 13 |
#7 | Sjöström Kjell | 13 |
#8 | Ågerstam Helena | 12 |
#9 | Sjostrom Kjell | 8 |
#10 | Agerstam Helena | 8 |
Publication | Filing date | Title |
---|---|---|
WO2020035577A1 | Anti-il1rap antibody compositions | |
AU2017343784A1 | Anti-IL1-RAP antibodies | |
GB201413913D0 | Novel antibodies and uses thereof | |
GB201403875D0 | Novel antibodies and uses thereof | |
CN107929730A | Anti- IL1RAP antibody and its purposes for treating the mankind | |
GB0914644D0 | IL1-RAP modulators and uses thereof |